Pulse nav.journalClub Debates activos Tendencias Explorar Investigadores

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

© Synapse Social LLC, 2026

Política de privacidad

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma | Synapse

February 12, 2013

Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Our results suggest potentially broad therapeutic use of BET bromodomain inhibitors for treating genetically diverse glioblastoma tumors.

Preguntar a la IA

Me gusta

Guardar

Compartir

Preguntar a la IA

Me gusta

Guardar

Compartir

Cite This Study

Cheng et al. (Tue,) studied this question.

synapsesocial.com/papers/69dd3f31fb7610310c10141e https://doi.org/https://doi.org/10.1158/1078-0432.ccr-12-3066

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel2007 · 203 citations
2c -MYC amplification and expression in astrocytic tumors2008 · 31 citations
3Identification of human brain tumour initiating cells2004 · 7,397 citations
4Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways2011 · 168 citations
5Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.2002 · 591 citations